TY - JOUR
T1 - Genomic instability decreases in hiv patient by complementary therapy with rosmarinus officinalis extracts
AU - Lazalde-Ramos, Blanca Patricia
AU - Zamora-Perez, Ana Lourdes
AU - Ortega-Guerrero, Aymée Ileana
AU - Quintero-Fraire, Saira Zulema
AU - Palacios-Lara, Omar
AU - Quirarte-Báez, Sol María
AU - Galaviz-Hernández, Carlos
AU - Sosa-Macias, Martha
AU - Ortiz-Garcia, Yveth Marlene
AU - Morales-Velazquez, Gabriela
N1 - Publisher Copyright:
© 2020 Mary Ann Liebert Inc.. All rights reserved.
PY - 2020/10
Y1 - 2020/10
N2 - Genomic instability is associated with increased oxidative stress in patients with human immunodeficiency virus (HIV). The aim of this study was to determine the effect of intake of methanolic and aqueous extracts of Rosmarinus officinalis on genomic instability in HIV patients. We studied 67 HIV patients under pharmacological treatment with ATRIPLA who were divided into three groups: group 1, patients under ATRIPLA antiretroviral therapy; group 2, patients with ATRIPLA and rosemary aqueous extract (4 g/L per day); and group 3, patients with ATRIPLA and rosemary methanolic extract (400 mg/day). The genomic instability was evaluated through the buccal micronucleus cytome assay. Oral epithelial cells were taken at the beginning and 1 and 4 months later. The groups that received the pharmacological therapy with ATRIPLA and the complementary therapy with R. officinalis extracts showed a decrease in the number of cells with micronuclei and nuclear abnormalities compared with the group that only received ATRIPLA. The complementary therapy with R. officinalis decreased the genomic instability in HIV patients.
AB - Genomic instability is associated with increased oxidative stress in patients with human immunodeficiency virus (HIV). The aim of this study was to determine the effect of intake of methanolic and aqueous extracts of Rosmarinus officinalis on genomic instability in HIV patients. We studied 67 HIV patients under pharmacological treatment with ATRIPLA who were divided into three groups: group 1, patients under ATRIPLA antiretroviral therapy; group 2, patients with ATRIPLA and rosemary aqueous extract (4 g/L per day); and group 3, patients with ATRIPLA and rosemary methanolic extract (400 mg/day). The genomic instability was evaluated through the buccal micronucleus cytome assay. Oral epithelial cells were taken at the beginning and 1 and 4 months later. The groups that received the pharmacological therapy with ATRIPLA and the complementary therapy with R. officinalis extracts showed a decrease in the number of cells with micronuclei and nuclear abnormalities compared with the group that only received ATRIPLA. The complementary therapy with R. officinalis decreased the genomic instability in HIV patients.
KW - Cytotoxicity
KW - DNA instability
KW - Genotoxicity
KW - HIV
KW - Nuclear abnormalities
KW - Rosmarinus officinalis
UR - http://www.scopus.com/inward/record.url?scp=85093539017&partnerID=8YFLogxK
U2 - 10.1089/jmf.2019.0199
DO - 10.1089/jmf.2019.0199
M3 - Artículo
C2 - 32125929
AN - SCOPUS:85093539017
SN - 1096-620X
VL - 23
SP - 1070
EP - 1076
JO - Journal of Medicinal Food
JF - Journal of Medicinal Food
IS - 10
ER -